HAVCR2 and neoplasm: Treatment with anti‐TIM3 monoclonal antibody effectively suppressed tumor growth through restoring effector T‐cell function by targeting CD4+TIM3+ cells and CD8+TIM3+ cells and decreasing MDSCs.